{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ta MH"],"funding":["National Health and Medical Research Council (AU)","National Health and Medical Research Council"],"pagination":["e0164193"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5056751"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(10)"],"pubmed_abstract":["The disease-modifying effects of target of rapamycin complex 1 (TORC1) inhibitors during different stages of polycystic kidney disease (PKD) are not well defined. In this study, male Lewis Polycystic Kidney Disease (LPK) rats (a genetic ortholog of human NPHP9, phenotypically characterised by diffuse distal nephron cystic growth) and Lewis controls received either vehicle (V) or sirolimus (S, 0.2 mg/kg by intraperitoneal injection 5 days per week) during the early (postnatal weeks 3 to 10) or late stages of disease (weeks 10 to 20). In early-stage disease, sirolimus reduced kidney enlargement (by 63%), slowed the rate of increase in total kidney volume (TKV) in serial MRI by 78.2% (LPK+V: 132.3±59.7 vs. LPK+S: 28.8±12.0% per week) but only partly reduced the percentage renal cyst area (by "],"journal":["PloS one"],"pubmed_title":["Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease."],"pmcid":["PMC5056751"],"funding_grant_id":["457575","632647"],"pubmed_authors":["Ta MH","Rangan GK","Schwensen KG","Korgaonkar M","Ozimek-Kulik JE","Phillips JK","Peduto A","Foster S"],"additional_accession":[]},"is_claimable":false,"name":"Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease.","description":"The disease-modifying effects of target of rapamycin complex 1 (TORC1) inhibitors during different stages of polycystic kidney disease (PKD) are not well defined. In this study, male Lewis Polycystic Kidney Disease (LPK) rats (a genetic ortholog of human NPHP9, phenotypically characterised by diffuse distal nephron cystic growth) and Lewis controls received either vehicle (V) or sirolimus (S, 0.2 mg/kg by intraperitoneal injection 5 days per week) during the early (postnatal weeks 3 to 10) or late stages of disease (weeks 10 to 20). In early-stage disease, sirolimus reduced kidney enlargement (by 63%), slowed the rate of increase in total kidney volume (TKV) in serial MRI by 78.2% (LPK+V: 132.3±59.7 vs. LPK+S: 28.8±12.0% per week) but only partly reduced the percentage renal cyst area (by ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016","modification":"2026-05-05T08:40:03.215Z","creation":"2019-03-26T22:48:26Z"},"accession":"S-EPMC5056751","cross_references":{"pubmed":["27723777"],"doi":["10.1371/journal.pone.0164193"]}}